Top

Published in:

01-08-2008 | Breast Oncology

Lumpectomy and Partial Breast Irradiation - Risks and Benefits for Early Breast Cancer

Authors: D. Ziogas, MD, E. Ignatiadou, MD, M. Fatouros, MD

Published in: Annals of Surgical Oncology | Issue 8/2008

Excerpt

Breast-conserving surgery followed by radiation therapy is the standard local treatment of early primary breast cancer.1 Radiation therapy limited to the part of the breast closest to the site of the excised tumor (accelerated partial breast irradiation, APBI) might be beneficial for these patients, but definitive results of ongoing trials should be awaited. Partial breast intraoperative radiation (IORT) has recently been developed to further improve the results of partial irradiation. Given that tumor-negative margins are required for IORT, Schiller et al.2 considered how to identify and select patients for IORT by predicting those with tumor-free excision margins. …

Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133–44PubMedCrossRef

Schiller DE, Le LW, Cho BC, et al. Factors associated with negative margins of lumpectomy specimen: potential use in selecting patients for intraoperative radiotherapy. Ann Surg Oncol 2007 Dec 28 [Epub ahead of print]

Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003; 10: 718–21PubMedCrossRef

Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357: 1555–6; author reply 1556PubMedCrossRef

Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002; 9:607–9PubMedCrossRef

Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 2008; 15(1):21–33.PubMedCrossRef

Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002; 9:941–3PubMed

Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4PubMedCrossRef

Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5;737–45PubMedCrossRef

10.

Early Breast Cancer Trialists’ Collaborative Group (Clarke M, Collins R, Darby S, et al.) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087–106PubMed

11.

Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98–107PubMedCrossRef

12.

Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999; 6:46–56PubMedCrossRef

13.

Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000;26:243–55PubMedCrossRef

14.

Roukos DH, Hottenrott C, Encke A, et al. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994;3:115–25PubMedCrossRef

15.

Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004; 11:127–9PubMedCrossRef

16.

Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; 14:2691–5PubMed

17.

Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9PubMedCrossRef

18.

Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002; 81:59–62PubMedCrossRef

19.

Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004; 11:727–30PubMedCrossRef

20.

Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998; 80:16–24PubMed

21.

Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000; 7:253–5PubMedCrossRef

22.

Roukos DH, Hottenrott C, Lorenz M, et al. A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. An analysis of early results and long-term survival. J Cancer Res Clin Oncol 1990; 116:307–11PubMedCrossRef

23.

Roukos DH, Lorenz M, Karakostas K, et al. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001; 84:1602–9PubMedCrossRef

24.

Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998;123:573–8PubMedCrossRef

25.

Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9:220–221PubMed

26.

Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39PubMedCrossRef

27.

Liakakos T, Roukos DH. More controversy than ever – Challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008; doi: 10.1245/s10434-007-9798-5.

28.

Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008; 358:197–198.PubMedCrossRef

29.

Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007; 4:578–90PubMedCrossRef

30.

Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12PubMedCrossRef

Title: Lumpectomy and Partial Breast Irradiation - Risks and Benefits for Early Breast Cancer
Authors: D. Ziogas, MD
E. Ignatiadou, MD
M. Fatouros, MD
Publication date: 01-08-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 8/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-008-9825-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lumpectomy and Partial Breast Irradiation - Risks and Benefits for Early Breast Cancer

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2008

The Lymphatic Anatomy of the Breast and Its Implications for Sentinel Lymph Node Biopsy: A Human Cadaver Study

Clinical Significance of Loss of Fhl1 Expression in Human Gastric Cancer

Flow Cytometric Analysis of DNA Ploidy and S-Phase Fraction in Primary Localized Myxofibrosarcoma: Correlations with Clinicopathological Factors, Skp2 Expression, and Patient Survival

Benign Papilloma on Core Biopsy Requires Surgical Excision

PDGF-BB is a Novel Prognostic Factor in Colorectal Cancer

A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination from Colorectal and Appendiceal Cancers